Gel formulations containing growth factors
AssigneeEthicon, Inc.
InventorsJohn Cini, Amy Finkenaur
Life of this patent
Estimating the term…
Abstract
Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, particularly in the anterior chamber of the eye. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
Claims36
A pharmaceutical composition comprising:
- a) an effective epidermal, ophthalmic or cutaneous wound healing amount of platelet derived growth factor (PDGF);
- b) a pharmaceutically acceptable cellulose polymer;
- and
- c) a pharmaceutically acceptable charged chemical species other than PDGF selected from the group consisting of lysine, arginine, histidine, protamine, alanine, methionine, proline, serine, asparagine, cysteine, aminoguanidine, zinc and magnesium, wherein the composition is an aqueous gel having a viscosity in the range of about 1000 to 500,000 cps at room temperature.
A pharmaceutical composition comprising:
- a) an effective epithelial, ophthalmic or cutaneous wound healing amount of human PDGF B homodimer;
- b) carboxymethylcellulose (CMC);
- and
- c) lysine, wherein the composition is an aqueous gel having a viscosity in the range of about 1000 to 500,000 cps at room temperature.
The composition of claim, 11 wherein the lysine concentration is within the range of about 0.1% (w/w) to about 3.0% (w/w).
A pharmaceutical composition, comprising:
- a) an effective epithelial, ophthalmic or cutaneous wound healing amount of platelet derived growth factor (PDGF);
- b) a pharmaceutically acceptable cellulose polymer at a concentration in the range of about 1.5% (w/w) to about 3.0% (w/w) and having a molecular weight in the range of about 450,000 to about 4,000,000;
- and
- c) a pharmaceutically acceptable positively charged chemical species other than PDGF selected from the group consisting of positively charged amino acids, positively charged polyamino acids and positively charged metal ions at a concentration in the range of about 0.1% (w/w) to about 3.0% (w/w), wherein the composition is an aqueous gel having a viscosity in the range of about 1000 to 500,000 cps at room temperature.
A pharmaceutical composition, comprising:
- a) an effective epidermal, ophthalmic or cutaneous wound healing amount of platelet derived growth factor (PDGF);
- b) a pharmaceutically acceptable cellulose polymer;
- and
- c) a pharmaceutically acceptable charged chemical species other than PDGF.
A pharmaceutical composition, comprising:
- a) an effective epidermal, ophthalmic or cutaneous wound healing amount of human PDGF B--B homodimer;
- b) carboxymethylcellulose (CMC);
- and
- c) lysine.
Dependencies are inferred from the claim text.